Compare · SYK vs TELA
SYK vs TELA
Side-by-side comparison of Stryker Corporation (SYK) and TELA Bio Inc. (TELA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYK and TELA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $115.59B, about 3037.9x TELA ($38.1M).
- Over the past year, SYK is down 18.3% and TELA is down 51.1% - SYK leads by 32.8 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 1 for TELA).
- SYK has more recent analyst coverage (25 ratings vs 2 for TELA).
- Company
- Stryker Corporation
- TELA Bio Inc.
- Price
- $312.25+3.53%
- $0.93+6.96%
- Market cap
- $115.59B
- $38.1M
- 1M return
- +9.36%
- -15.53%
- 1Y return
- -18.29%
- -51.09%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 8
- 1
- Recent ratings
- 25
- 2
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
TELA Bio Inc.
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation
Latest TELA
- After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
- Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.
- SEC Form 10-Q filed by TELA Bio Inc.
- TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TELA Bio Reports First Quarter 2026 Financial Results
- TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form DEFA14A filed by TELA Bio Inc.
- SEC Form DEF 14A filed by TELA Bio Inc.
- TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update
- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues